Effect of Bupropion SR on the Quality of Life of Elderly Depressed Patients With Comorbid Medical Disorders

Fortner, Molly; Brown, Kristine M.; Varia, Indira; Gersing, Kenneth; O’Connor, Christopher M.; Doraiswamy, P. Murali

doi:10.4088/pcc.v01n0601

Cited by 9 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This effect also has been observed in the treatment of fatigue in cancer patients [24]. Dopaminergic Agents With Potential to Improve Quality of Life in Major Depressive Disorder Preliminary evidence shows that bupropion monotherapy signifi cantly improved QOL in MDD in the two studies reviewed in this article [25,26]. Of importance, bupropion is frequently used as an augmentation strategy for depressed patients who are nonresponsive or partially responsive to antidepressant regimens.…”

Section: Characteristics Of Dopaminergic Agents Andmentioning

confidence: 84%

“…In preliminary studies, bupropion has been shown to improve QOL signifi cantly in MDD [25,26]. Several explanations have been postulated for this effect, including the absence of side effects such as sexual dysfunction and sedation.…”

Section: Discussionmentioning

confidence: 97%

“…The "vitality" domain also improved signifi cantly by week 12. These fi ndings suggest that bupropion may improve QOL in patients with MDD and comorbid medical disorders [25].…”

Section: Evidence Of Specifi C Improvement In Quality Of Life In Majomentioning

confidence: 97%

“…Fortner et al [25] examined the effect of bupropion SR on QOL in older adults with MDD and comorbid medical disorders. Bupropion SR (mean dose, 222 mg/d) was administered acutely for 8 weeks to 18 older adults (60-81 years of age) with MDD and a broad range of serious medical conditions.…”

Section: Evidence Of Specifi C Improvement In Quality Of Life In Majomentioning

confidence: 99%

See 3 more Smart Citations

The role of dopaminergic agents in improving quality of life in major depressive disorder

IsHak

Davis²,

Jeffrey³

et al. 2009

Curr Psychiatry Rep

View full text Add to dashboard Cite

Quality of life (QOL) is greatly diminished in patients with major depressive disorder (MDD) before treatment. This deficit persists even when patients are in remission; thus, interventions are needed to improve QOL. This article reviews QOL impairment in MDD and the cost of impairment, then summarizes the empiric literature on the effects of dopaminergic agents on QOL in patients with MDD. Studies were identified through a MEDLINE search from the past 35 years (1974-2009) using key terms "quality of life," "major depression," and "major depressive disorder," and "dopaminergic," "bupropion," or "modafinil." A total of 47 studies were included in this review. A brief overview of the relationship between QOL and MDD is presented, followed by a review of dopaminergic agent chemistry, mechanism of action, use, and trials conducted to investigate agents' effects on QOL. Preliminary evidence suggests dopaminergic agents may have a positive effect on QOL for patients with MDD. Prospective, randomized, double-blind, placebo-controlled studies are needed to extend these findings.

show abstract

Section: Characteristics Of Dopaminergic Agents Andmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 97%

“…The "vitality" domain also improved signifi cantly by week 12. These fi ndings suggest that bupropion may improve QOL in patients with MDD and comorbid medical disorders [25].…”

Section: Evidence Of Specifi C Improvement In Quality Of Life In Majomentioning

confidence: 97%

Section: Evidence Of Specifi C Improvement In Quality Of Life In Majomentioning

confidence: 99%

See 2 more Smart Citations

The role of dopaminergic agents in improving quality of life in major depressive disorder

IsHak

Davis²,

Jeffrey³

et al. 2009

Curr Psychiatry Rep

View full text Add to dashboard Cite

show abstract

“…50 When quality of life (QOL) was examined in elderly patients with MDD and medical comorbidities, bupropion SR significantly improved scores on the Medical Outcomes Study Short Form-36 (SF-36), with "mental health" (P , 0.01) and "social functioning" (P , 0.0006) improving by week 4 and "vitality" (P , 0.03) improving by week 12. 51 Additionally, bupropion SR was relatively well-tolerated with significant efficacy findings as shown by reductions in the Clinical Global Impressions-Severity of Illness scale (P , 0.0001) and in the HAM-D total score (P , 0.0001). 51 When correlations were measured between improvements in depression severity and QOL, another study on bupropion SR found that there were significant correlations between improvements in HAM-D total score and the Quality-of-Life in Depression Scale (QLDS) score (r 2 = 0.12; P , 0.0004) as well as between HAM-D and the SF-36 Mental Component score (r 2 = 0.20; P , 0.0001) but not between HAM-D and the SF-36 Physical Component score (r 2 = 0.06; P , 0.014).…”

Section: Role In Geriatric Depressionmentioning

confidence: 98%

The Role of Bupropion in the Management of Major Depressive Disorder

2011

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

Bupropion is an antidepressant of the aminoketone class that is chemically unrelated to any other known antidepressant agent. In the treatment of major depressive disorder (MDD), bupropion has shown comparable therapeutic efficacy to selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs). Bupropion effectiveness in treating co-morbid fatigue, hypersomnia, anhedonia, and mild to moderate anxiety symptoms (contrary to common clinician beliefs) associated with MDD is well documented. It is generally well tolerated with minimal undesirable side effects associated with antidepressants, such as sexual dysfunction and weight gain. Bupropion has shown effectiveness in augmentation as well as in switching strategies of antidepressant medications. Due to its favorable side-effect profile, bupropion has been used in the treatment of geriatric depression with good therapeutic efficacy and health outcome measurements. Bupropion has also shown usefulness as a smoking cessation agent and in treating depression in patients with medical co-morbidities such as asthma and HIV. Limitations of use include individuals at risk for seizures and patients with eating disorders.

show abstract

Pharmacosexology: Psychiatric Side Effects of Drugs for the Treatment of Sexual Dysfunction

Abdo

2018

Trends in Andrology and Sexual Medicine

View full text Add to dashboard Cite

Effect of Bupropion SR on the Quality of Life of Elderly Depressed Patients With Comorbid Medical Disorders

Cited by 9 publications

References 11 publications

The role of dopaminergic agents in improving quality of life in major depressive disorder

The role of dopaminergic agents in improving quality of life in major depressive disorder

The Role of Bupropion in the Management of Major Depressive Disorder

Pharmacosexology: Psychiatric Side Effects of Drugs for the Treatment of Sexual Dysfunction

Contact Info

Product

Resources

About